Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Methotrexate and its drug resistance].

E Nagura1

  • 1Dept. of Medicine, National Chubu Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|October 1, 1988
PubMed
Summary

Methotrexate (MTX) resistance in cancer therapy involves decreased cell permeability and altered dihydrofolate reductase (DHFR) activity. High-dose MTX shows limited efficacy, necessitating further research for improved cancer treatment strategies.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Trends of survival in patients with multiple myeloma in Japan: a multicenter retrospective collaborative study of the Japanese Society of Myeloma.

Blood cancer journal·2015
Same author

Posttreatment nadir M-protein level is a stronger discriminator of survival following plateau attainment than is percent reduction in M-protein in patients with IgG myeloma.

International journal of hematology·2001
Same author

Acute myeloid leukemia in the elderly:--159 Nagoya case studies--Nagoya Cooperative Study Group for Elderly Leukemia.

Nagoya journal of medical science·2000
Same author

Posttreatment M-protein nadir level is a significant prognostic factor associated with survival in multiple myeloma. Nagoya Myeloma Cooperative Study Group.

Japanese journal of cancer research : Gann·1999
Same author

[Analysis of elderly patients, aged 60 years old or over, with acute lymphoblastic leukemia].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·1999
Same author

[Characteristics of bedridden elderly people living at home and in a hospital].

Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·1997

Area of Science:

  • Oncology and Pharmacology
  • Molecular Biology

Context:

  • Methotrexate (MTX) is a key antifolate drug in cancer chemotherapy.
  • Mechanisms of MTX resistance are well-documented, including reduced cellular uptake and altered target enzyme dynamics.
  • Dihydrofolate reductase (DHFR) is the primary target enzyme for MTX.

Purpose:

  • To review the known mechanisms of methotrexate resistance in cancer therapy.
  • To evaluate the clinical efficacy of high-dose methotrexate (HDMTX) in overcoming resistance.
  • To identify areas for future research to enhance MTX-based cancer treatments.

Summary:

  • MTX resistance arises from decreased cell permeability, increased DHFR synthesis due to gene amplification, reduced MTX polyglutamation, and diminished MTX binding to DHFR.
  • High-dose MTX (HDMTX) therapy aims to overcome resistance by saturating DHFR and its polyglutamated forms.
  • Clinical trials of HDMTX have shown limited success, with notable efficacy only in specific cancers like childhood acute lymphoblastic leukemia (ALL) and osteosarcoma.

Impact:

  • Understanding MTX resistance mechanisms is crucial for developing more effective antifolate therapies.
  • The limited clinical success of HDMTX highlights the need for novel strategies to improve MTX efficacy.
  • Further research is essential to optimize MTX-based cancer treatment protocols and overcome resistance in various malignancies.

Related Experiment Videos